多机构列线图预测脑转移瘤放疗后免于挽救性全脑放疗的生存
本研究基于895例2095个病灶的多机构数据,建立列线图预测脑转移瘤患者 upfront 立体定向放射外科(SRS)后免于挽救性全脑放疗(WBRT)的生存。中位WBRT-free生存为8个月,列线图纳入年龄、HER2(-)乳腺癌、结直肠癌、脑转移灶数目、神经系统症状、系统性病变进展及颅外病变负荷等独立预测因子,校正Harrell C统计量为0.62。该列线图可用于初始评估,帮助筛选最适合 upfront SRS 的患者。
要点
- 列线图预测6个月和12个月WBRT-free生存概率,校正C统计量0.62。
- 独立预测因子包括年龄、HER2(-)乳腺癌、结直肠癌、脑转移灶数目、神经系统症状、系统性病变进展及颅外病变负荷。
- 中位WBRT-free生存为8个月(范围0.1-139个月)。
核心结论
- 列线图可用于初始评估,帮助选择最适合 upfront SRS 的脑转移瘤患者,并减少对获益甚微或无获益患者的费用和并发症。
研究设计与样本
- 多机构回顾性分析纳入895例2095个病灶,患者接受SRS且无既往或计划WBRT,采用Cox比例风险回归识别独立预测因子并构建列线图,经bootstrap验证。
主要发现
- 中位WBRT-free生存为8个月(范围0.1-139个月)。
- 年龄每增加10年HR 1.1;HER2(-)乳腺癌HR 1.6;结直肠癌HR 1.4;脑转移灶数目2、3、4、5+个的HR分别为1.09、1.32、1.37、1.87;神经系统症状HR 1.26;系统性病变进展HR 1.35;颅外病变负荷寡转移HR 1.31、广泛转移HR 1.56。
- HER2(+)乳腺癌HR 0.81和黑色素瘤HR 1.11趋势 toward 显著性。
- 列线图显示6个月和12个月WBRT-free生存的估计概率,校正Harrell C统计量为0.62。
关键数值与推荐
- 列线图纳入的独立预测因子包括年龄、HER2(-)乳腺癌、结直肠癌、脑转移灶数目、神经系统症状、系统性病变进展及颅外病变负荷。
- 列线图提供6个月和12个月WBRT-free生存的估计概率。
临床怎么用
- 在初始评估时使用列线图估计WBRT-free生存概率,辅助筛选适合 upfront SRS 的患者。
- 对预测获益甚微或无获益的患者,可避免不必要的SRS相关费用和并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal patient selection for stereotactic radiosurgery (SRS) as the initial treatment for brain metastases is complicated and controversial. This study aimed to develop a nomogram that predicts survival without salvage whole brain radiation therapy (WBRT) after upfront SRS. METHODS AND MATERIALS: Multi-institutional data were analyzed from 895 patients with 2095 lesions treated with SRS without prior or planned WBRT. Cox proportional hazards regression model was used to identify independent pre-SRS predictors of WBRT-free survival, which were integrated to build a nomogram that was subjected to bootstrap validation. RESULTS: Median WBRT-free survival was 8 months (range, 0.1-139 months). Significant independent predictors for inferior WBRT-free survival were age (hazard ratio [HR] 1.1 for each 10-year increase), HER2(-) breast cancer (HR 1.6 relative to other histologic features), colorectal cancer (HR 1.4 relative to other histologic features), increasing number of brain metastases (HR 1.09, 1.32, 1.37, and 1.87 for 2, 3, 4, and 5+ lesions, respectively), presence of neurologic symptoms (HR 1.26), progressive systemic disease (HR 1.35), and increasing extracranial disease burden (HR 1.31 for oligometastatic and HR 1.56 for widespread). Additionally, HER2(+) breast cancer (HR 0.81) and melanoma (HR 1.11) trended toward significance. The independently weighted hazard ratios were used to create a nomogram to display estimated probabilities of 6-month and 12-month WBRT-free survival with a corrected Harrell's C concordance statistic of 0.62. CONCLUSIONS: Our nomogram can be used at initial evaluation to help select patients best suited for upfront SRS for brain metastases while reducing expense and morbidity in patients who derive minimal or no benefit.
引用
- Gorovets D, Ayala-Peacock D, Tybor DJ, et al. Multi-institutional Nomogram Predicting Survival Free From Salvage Whole Brain Radiation After Radiosurgery in Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2016. PMID: 28068233. doi:10.1016/j.ijrobp.2016.09.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。